These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19521329)

  • 1. Alcohol as a potential contributing factor in radiation complications.
    Matthews RH; Kadoch C; Ercal N
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):257-62. PubMed ID: 19521329
    [No Abstract]   [Full Text] [Related]  

  • 2. Review: alcohol and other factors related to late prostate radiation injury.
    Koontz BF; Vujaskovic Z
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):262. PubMed ID: 19521330
    [No Abstract]   [Full Text] [Related]  

  • 3. Intermediate- to high-risk prostate cancer patient treated with radiation therapy.
    Crawford ED; Barqawi A
    Oncology (Williston Park); 2004 Aug; 18(9):1105-10. PubMed ID: 15471196
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating prostate cancer: another step forward.
    Harv Mens Health Watch; 1998 May; 2(10):7. PubMed ID: 9577263
    [No Abstract]   [Full Text] [Related]  

  • 5. RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
    Oncology (Williston Park); 2005 Aug; 19(9):1142. PubMed ID: 16402596
    [No Abstract]   [Full Text] [Related]  

  • 6. Permanent localized hair repigmentation following herpes zoster infection.
    Adiga GU; Rehman KL; Wiernik PH
    Arch Dermatol; 2010 May; 146(5):569-70. PubMed ID: 20479318
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer.
    Repka MC; Kole TP; Lee J; Wu B; Lei S; Yung T; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Acta Oncol; 2017 Aug; 56(8):1136-1138. PubMed ID: 28270015
    [No Abstract]   [Full Text] [Related]  

  • 8. ASTRO plenary session touts top new research. American Society for Therapeutic Radiology and Oncology.
    Volkers N
    J Natl Cancer Inst; 1999 Dec; 91(24):2075-7. PubMed ID: 10601375
    [No Abstract]   [Full Text] [Related]  

  • 9. Androgen deprivation therapy for patients with prostate carcinoma and Parkinson's disease: case report and review of literature.
    Elshaikh MA; Underwood W; Soto DE
    Can J Urol; 2009 Feb; 16(1):4495-7. PubMed ID: 19222889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate cancer: radiotherapy or operation?].
    Aktuelle Urol; 2013 Mar; 44(2):103-4. PubMed ID: 23592289
    [No Abstract]   [Full Text] [Related]  

  • 11. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
    Miller K
    MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
    [No Abstract]   [Full Text] [Related]  

  • 12. Goserelin.
    Nurs Times; 2006 Jan 17-23; 102(3):41. PubMed ID: 16440976
    [No Abstract]   [Full Text] [Related]  

  • 13. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
    Denham JW; Steigler A; Wilcox C; Lamb DS; Joseph D; Atkinson C; Tai KH; Spry NA; Gleeson PS; D'Este C
    Cancer; 2009 Oct; 115(19):4477-87. PubMed ID: 19691097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer.
    Buyyounouski MK
    Eur Urol; 2014 Dec; 66(6):1031-2. PubMed ID: 25130566
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate.
    Lilleby W; Axcrona K; Alfsen GC; Urnes T; Hole KH
    Acta Oncol; 2007; 46(8):1195-7. PubMed ID: 17851841
    [No Abstract]   [Full Text] [Related]  

  • 16. [Edifications and modern strategies of localized prostate cancers' definitive therapy].
    Varga L; Bajory Z; Pajor L; Révész J; Sükösd F; Maráz A
    Orv Hetil; 2018 Aug; 159(32):1317-1325. PubMed ID: 30078360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical outcomes of treatment for prostate cancer.
    Vicini FA; Kestin L; Martinez A
    JAMA; 2000 Dec; 284(22):2869. PubMed ID: 11147976
    [No Abstract]   [Full Text] [Related]  

  • 18. Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2.
    Fiorino C; Briganti A; Cozzarini C
    Eur Urol; 2015 Mar; 67(3):e56-7. PubMed ID: 25466947
    [No Abstract]   [Full Text] [Related]  

  • 19. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of luteinizing hormone-releasing hormone agonists on behavior in a patient with dementia.
    Beversdorf DQ; Tomasi MJ
    J Clin Psychopharmacol; 2009 Feb; 29(1):101-2. PubMed ID: 19142125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.